WEKO3
アイテム
Strategies for utilizing neuroimaging biomarkers in CNS drug discovery and development: CINP/JSNP working group report.
https://repo.qst.go.jp/records/47786
https://repo.qst.go.jp/records/47786f59ad8f1-3e36-444a-8e93-b0a98208d788
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-01-04 | |||||
| タイトル | ||||||
| タイトル | Strategies for utilizing neuroimaging biomarkers in CNS drug discovery and development: CINP/JSNP working group report. | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Suhara, Tetsuya
× Suhara, Tetsuya× Chaki, Shigeyuki× Kimura, Haruhide× Furusawa, Makoto× Matsumoto, Mitsuyuki× Ogura, Hiroo× Negishi, Takaaki× Saijo, Takeaki× Higuchi, Makoto× Omura, Tomohiro× Watanabe, Rira× Miyoshi, Sosuke× Nakatani, Noriaki× Yamamoto, Noboru× Shyh-Yuh, Liou× Takado, Yuhei× Maeda, Jun× Okamoto, Yasumasa× Okubo, Yoshiaki× Yamada, Makiko× Ito, Hiroshi× M Walton, Noah× Yamawaki, Shigeto× Suhara, Tetsuya× Higuchi, Makoto× Takado, Yuhei× Maeda, Jun× Yamada, Makiko |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Despite large unmet medical needs in the field for several decades, central nervous system (CNS) drug discovery and development has been largely unsuccessful. Biomarkers, particularly those utilizing neuroimaging, have played important roles in aiding CNS drug development, including dosing determination of investigational new drugs (INDs). The utility of biomarkers as tools to overcome issues of CNS drug development is the subject for this review.In this review aimed at employing biomarkers as tools to overcome issues surrounding CNS drug development, we first analyzed problems in utilizing biomarkers in processes of drug discovery and development for CNS disorders. Based on this analysis, we propose a new paradigm containing five distinct tiers to further clarify the use of biomarkers and establish new strategies for decision-making in the context of clinical drug development. Specifically, we discuss more rational ways to determine optimal dose for INDs with novel mechanisms and targets, and propose additional categorization criteria to further the use of biomarkers in patient stratification and efficacy prediction. Finally, we propose validation and development of new neuroimaging biomarkers through Public-Private-Partnerships to realize rational and successful drug discovery and development for CNS disorders. | |||||
| 書誌情報 |
The international journal of neuropsychopharmacology 巻 20, 号 4, p. 285-294, 発行日 2016-12 |
|||||
| 出版者 | ||||||
| 出版者 | Oxford University Press | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1461-1457 | |||||
| PubMed番号 | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 28031269 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1093/ijnp/pyw111 | |||||
